Literature DB >> 28772306

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial.

Olivier Caron1, Thierry Frebourg2,3, Patrick R Benusiglio1, Stéphanie Foulon4,5, Laurence Brugières6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28772306      PMCID： PMC5824279          DOI： 10.1001/jamaoncol.2017.1358

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.

Authors:  Phuong L Mai; Ana F Best; June A Peters; Rosamma M DeCastro; Payal P Khincha; Jennifer T Loud; Renée C Bremer; Philip S Rosenberg; Sharon A Savage
Journal:  Cancer       Date:  2016-08-06       Impact factor: 6.860

2.  TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.

Authors:  Marielle W G Ruijs; Senno Verhoef; Matti A Rookus; Roelof Pruntel; Annemarie H van der Hout; Frans B L Hogervorst; I Kluijt; Rolf H Sijmons; Cora M Aalfs; Anja Wagner; Margreet G E M Ausems; Nicoline Hoogerbrugge; Christi J van Asperen; Encarna B Gomez Garcia; Hanne Meijers-Heijboer; Leo P Ten Kate; Fred H Menko; Laura J van 't Veer
Journal:  J Med Genet       Date:  2010-06       Impact factor: 6.318

3.  Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

Authors:  Gaëlle Bougeard; Mariette Renaux-Petel; Jean-Michel Flaman; Camille Charbonnier; Pierre Fermey; Muriel Belotti; Marion Gauthier-Villars; Dominique Stoppa-Lyonnet; Emilie Consolino; Laurence Brugières; Olivier Caron; Patrick R Benusiglio; Brigitte Bressac-de Paillerets; Valérie Bonadona; Catherine Bonaïti-Pellié; Julie Tinat; Stéphanie Baert-Desurmont; Thierry Frebourg
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.

Authors:  Anita Villani; Ari Shore; Jonathan D Wasserman; Derek Stephens; Raymond H Kim; Harriet Druker; Bailey Gallinger; Anne Naumer; Wendy Kohlmann; Ana Novokmet; Uri Tabori; Marta Tijerin; Mary-Louise C Greer; Jonathan L Finlay; Joshua D Schiffman; David Malkin
Journal:  Lancet Oncol       Date:  2016-08-05       Impact factor: 41.316

5.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

Review 6.  Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.

Authors:  Junne Kamihara; Huma Q Rana; Judy E Garber
Journal:  Hum Mutat       Date:  2014-06       Impact factor: 4.878
  6 in total
  9 in total

1.  Molecular diagnosis and clinical outcome of a lung cancer patient with TP53-E285K mutated Li-Fraumeni syndrome harboring a somatic EGFR-KDD mutation.

Authors:  Dafu Yang; Xue Han; Dan Li; Saiqiong Cui; Sisi Liu; Xue Wu; Zhaoxia Dai
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

2.  Lung Cancer in Li-Fraumeni Syndrome.

Authors:  Kathleen Kerrigan; Jessica Chan; Jennie Vagher; Wendy Kohlmann; Anne Naumer; Jo Anson; Sara Low; Joshua Schiffman; Luke Maese
Journal:  JCO Precis Oncol       Date:  2021-03-23

Review 3.  Epidemiology and clinicopathological features of lung cancer in patients with prior history of breast cancer.

Authors:  Kevin Y Wang; James Newman; Chung-Shien Lee; Nagashree Seetharamu
Journal:  SAGE Open Med       Date:  2021-05-25

4.  Lung Cancer as a Subsequent Malignant Neoplasm in Survivors of Childhood Cancer.

Authors:  Taumoha Ghosh; Yan Chen; Andrew C Dietz; Gregory T Armstrong; Rebecca M Howell; Susan A Smith; Daniel A Mulrooney; Lucie M Turcotte; Yan Yuan; Yutaka Yasui; Joseph P Neglia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-09-14       Impact factor: 4.090

Review 5.  Inherited lung cancer: a review.

Authors:  Viviane Teixeira Loiola de Alencar; Maria Nirvana Formiga; Vladmir Cláudio Cordeiro de Lima
Journal:  Ecancermedicalscience       Date:  2020-01-29

6.  Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.

Authors:  Thierry Frebourg; Svetlana Bajalica Lagercrantz; Carla Oliveira; Rita Magenheim; D Gareth Evans
Journal:  Eur J Hum Genet       Date:  2020-05-26       Impact factor: 4.246

7.  Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?

Authors:  Igor Araujo Vieira; Tiago Finger Andreis; Bruna Vieira Fernandes; Maria Isabel Achatz; Gabriel S Macedo; Daniel Schramek; Patricia Ashton-Prolla
Journal:  Front Genet       Date:  2021-02-02       Impact factor: 4.599

8.  Blood functional assay for rapid clinical interpretation of germline TP53 variants.

Authors:  Sabine Raad; Marion Rolain; Sophie Coutant; Céline Derambure; Raphael Lanos; Françoise Charbonnier; Jacqueline Bou; Emilie Bouvignies; Gwendoline Lienard; Stéphanie Vasseur; Michael Farrell; Olivier Ingster; Stéphanie Baert Desurmont; Edwige Kasper; Gaëlle Bougeard; Thierry Frébourg; Isabelle Tournier
Journal:  J Med Genet       Date:  2020-10-13       Impact factor: 6.318

9.  Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53.

Authors:  Emma Tham; Svetlana Bajalica-Lagercrantz; Meis Omran; Lennart Blomqvist; Yvonne Brandberg; Niklas Pal; Per Kogner; Anne Kinhult Ståhlbom
Journal:  Hered Cancer Clin Pract       Date:  2020-01-13       Impact factor: 2.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.